Vector Characterization Methods for Quality Control Testing of Recombinant Adeno-Associated Viruses

Methods in Molecular Biology

Volumn 737, Issue , 2011, Pages 247-278

  Wright, J Fraser ^a   Zelenaia, Olga ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

Clinical trials; Quality control; Recombinant AAV; Vector characterization

Indexed keywords

RECOMBINANT DNA;

ADENO ASSOCIATED VIRUS; ARTICLE; CELL LINE; CLINICAL TRIAL (TOPIC); CULTURE TECHNIQUE; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; SAFETY; STANDARD; TITRIMETRY; VIRION; VIRUS GENOME; WORKFLOW;

CELL CULTURE TECHNIQUES; CELL LINE; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; DNA, RECOMBINANT; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE THERAPY; GENETIC VECTORS; GENOME, VIRAL; GUIDELINES AS TOPIC; HUMANS; POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; SAFETY; TITRIMETRY; TRANSDUCTION, GENETIC; VIRION; WORKFLOW;

EID: 80052335519     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-095-9_11     Document Type: Chapter

References (29)

1. Carter, B.J. (2005). Adeno-associated virus vectors in clinical trials. Hum Gene Ther. 16, 541–550.
2. Warrington, K.H. and Herzog, R.W. (2006). Treatment of human disease by adeno-associated viral gene transfer. Hum Genet. 119, 571–603.
3. Fiandaca, M., Forsayeth, J., and Bankiewicz, K. (2008). Current status of gene therapy trials for Parkinson’s disease. Exp Neurol. 209, 51–57.
4. Christine, W.C., Starr, P., Larson, P., Eberling, J.L., Jagust, W.J., Hawkins, R., et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662–1669.
5. Maguire, A.M., High, K.A., Auricchio, A., Wright, J.F., Pierce, E.A., Testa, F., et al. (2009). Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374, 1597–1605.
6. 21CFR Parts 120 and 211 – Current Good Manufacturing Practice in manufacturing, processing, packing or holding of drugs; General and current Good Manufacturing Practice for finished pharmaceuticals. http:// www.access.gpo.gov/nara/cfr/index.html
7. US Dept Health Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for FDA and Sponsors: Content and review of Chemistry, Manufacturing, and Control (CMC) information for human gene therapy Investigational New Drug applications (INDs). November, 2004. http://www.fda.gov/cber/guidelines.htm
8. US Dept Health Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: INDs – Approaches to complying with CGMP during Phase 1. January 2006. http://www.fda.gov/cber/guidelines.htm
9. Gombold, J., Peden, K., Gavin, D., Wei, Z., Baradaran, K., Mire-Sluis, A., and Schenerman, M..(2006). Lot release and characterization testing of live-virus-based vaccines and gene therapy products, Part 1: Factors influencing assay choices. BioProcess Int. 4, 46–56.
10. Muzyczka, N. (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158, 97–129.
11. Allen, J.M., Debelak, D.J., Reynolds, T.C., and Miller, A.D. (1997). Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by non-homologous recombination during AAV vector production. J. Virol. 71, 6816–6822.
12. Samulski, R.J., Shang, L.-S., and Shenk, T. (1989). Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 61, 3096–3101.
13. Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J.A. (1998). Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9, 2745–2760.
14. Clark, K.R., Liu, X., McGrath, J.P., and Johnson, P.R. (1999). Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type virus. Hum. Gene Ther. 10, 1031–1039.
15. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Draft Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. October 2008. http://www.fda.gov/cber/guidelines. htm
16. Grimm, D., Kern, A., Pawlita, M., Ferrari, F.K., Samulski, R.J., and Kleinschmidt, J.A. (1999). Titration of AAV-2 particles via a novel capsid ELISA: Packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 5, 1322–1330.
17. Sommer, J.M., Smith, P.H., Parthasarathy, S., Isaacs, J., Vijay, S., Kieran, J., et al. (2003). Quantification of adeno-associated virus vectors and empty capsids by optical density measurement. Mol. Ther. 7, 122–128.
18. Chadeuf, G., Ciron, C., Moullier, P., and Salvetti, A (2005). Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther. 12, 744–753.
19. Report from the CHMP gene therapy expert group meeting. European Medicines Agency 2005; EMEA/CHMP/183989/2004. w ww.emea.europa.eu/pdfs/human/ genetherapy/18398904en.pdf
20. Hauck, B., Murphy, S., Smith, P.H., Qu, G., Liu, X., Zelenaia, O., et al. (2009). Undetectable transcription of cap in a clinical AAV vector: Implications for preformed capsid in immune responses. Mol. Ther. 17, 144–152.
21. Smith, P.H., Wright, J.F., Qu, G., Patarroyo White, S., Parker, A., and Sommer, J.M. (2003). Packaging of host cell and plasmid DNA into recombinant adeno-associated virus vectors produced by triple transfection. Mol. Ther. 7, S348.
22. EMEA Committee for Medicinal Products for Human Use (CHMP). Questions and Answers on Gene therapy. EMA/CHMP/GTWP/ 212377/2008. http://www.ema.europa.eu/pdfs/human/genetherapy/21237708en.pdf
23. US Dept Health Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry: Comparability protocols – Protein drug products and biological products – Chemistry, Manufacturing, and Controls information. September 2003. http://www.fda.gov/cber/guidelines.htm
24. US Dept Health Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: Analytical procedures and methods validation. Chemistry, manufacturing and controls documentation. August 2000. http://www.fda.gov/cber/guidelines.htm
25. US Dept Health Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: Q1A (R2) Stability testing of new drug substances and products. November 2003. http://www.fda.gov/cber/guidelines.htm
26. Sambrook, J., and Russell, D.W. (2001). Molecular cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
27. Clark, K.R., Voulgaropoulou, F., Fraley, D.M., and Johnson, P.R. (1995). Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. 6, 1329–1341.
28. Zhen, Z., Espinoza, Y., Bleu, T., Sommer, J.M., and Wright, J.F. (2004). Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum. Gene Ther. 15, 709–715.
29. Simpson, R.J. (2009). Stabilization of Proteins for Storage. In Basic Methods in Protein Purification and Analysis. Eds. Simpson R.J., Adams, P.D., and Golemis, E.A. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 385–400.